Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Age-dependent hippocampal proteomics in the APP/PS1 Alzheimer mouse model: a comparative analysis with classical SWATH/DIA and directDIA approaches

ABSTRACT: Alzheimer’s disease (AD) is the most common neurodegenerative disorder in the human population, for which there is currently no cure. The cause of AD is unknown, however, the toxic effects of amyloid-β (Aβ) are believed to play a role in its onset. To investigate this, we examined changes in global protein levels in a hippocampal synaptosome fraction of the APP/PS1 mouse model of AD at 6 and 12 months of age (moa). Data independent acquisition (DIA), or SWATH, was used for a quantitative label-free proteomics analysis. We first assessed the usefulness of a recently improved directDIA workflow as alternative to conventional DIA data analysis using a project specific spectral library. Subsequently, we applied directDIA to the 6- and 12-moa APP/PS1 datasets and applied the Mass Spectrometry Downstream Analysis Pipeline (MS-DAP) for differential expression analysis and candidate discovery. We observed most regulation at 12-moa, in particular of proteins involved in Aβ homeostasis and microglial dependent synaptic pruning and/or immune response, such as APOE, CLU and C1QA-C

INSTRUMENT(S): TripleTOF 5600

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Brain

DISEASE(S): Alzheimer's Disease

SUBMITTER: Sophie van der Spek

LAB HEAD: Ka Wan Li

PROVIDER: PXD025777 | Pride | 2021-06-24

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	12_APP_1.wiff	Wiff
	12_APP_1.wiff.scan	Wiff
	12_APP_2.wiff	Wiff
	12_APP_2.wiff.scan	Wiff
	12_APP_3.wiff	Wiff

Items per page:

1 - 5 of 94

Similar Datasets

Multifactorial neuroprotective effects of BNN27, a Nerve Growth Factor mimetic, in the 5xFAD mouse model of Alzheimer’s Disease

Project description:Neurotrophic factors consist major regulatory molecules and their decline in Alzheimer's disease is considered as an important cause of disease progression. Novel pharmacological approaches are targeting the downstream pathways controlled by neurotrophins, such as nerve growth factor (NGF) receptors, TrkA and p75NTR, which enhance hippocampal neurogenic capacity and neuroprotective mechanisms, and potentially counteract the neurotoxic effects of amyloid depositions. In this context, BNN27 is a newly developed 17-spiro-steroid analog that have previously shown to mimic the neuroprotective effects of NGF, acting as selective activator of its receptors, both TrkA and p75NTR, promoting neuronal survival. Our present research work aims at determining whether and which aspects of the AD-related pathology, BNN27 is able to alleviate, exploring the cellular and molecular components and link these changes with improvements in the cognitive performance of a mouse AD model. Our results clearly indicate that BNN27 administration significantly reduced amyloid-β load in whole brain, enhanced adult hippocampal neurogenesis, restored cholinergic neurons function and synaptogenesis, reducing inflammatory activation and leading to significant restoration of cognitive functions.

2024-11-25 | PXD044699 | Pride

Age-dependent changes in the gene expression profile of mice over-expressing mutant APP, PS1 and phosphorilated tau

Project description:In this study, using a microarray approach, we investigated the age-dependent changes in the gene expression profile of hippocampi obtained from young and old 3xTg-AD and WT control mice, in order to identify the molecular mechanisms involved in the development of AD and assess the role of aging in the development of the disease. A global gene expression profile in the hippocampi obtained from 3xTgAD (expressing mutant human APP, PS1, and tau) and WT mice at 3 and 12 months of age was studied by employing a Mouse OneArray Whole Genome DNA microarray. Data were analyzed with the Ingenuity Pathways Analysis (IPA) in order to achieve a classification of the results on the basis of their biological functions and disclose functional networks and/or pathways. In this study we performed gene expression profiles for a total of 9 experiments. Hippocampi were collected from 2 3xTG and 2 WT mice at 3 months of age and from 2 3xTG and 2 WT mice at 12 months of age. Three MicroArray experiments were performed for each condition (WT 12 moa versus WT 3 moa; 3xTG 3 moa versus WT 3 moa; 3xTG 12 moa versus WT 12moa). On the total of 9 experiments 6 were biological replicates and 3 were technical replicates.

2012-06-27 | E-GEOD-35210 | biostudies-arrayexpress

Suspension TRAPping filter (sTRAP) sample preparation for quantitative proteomics in the low µg input range using a plasmid DNA micro-spin column: analysis of the hippocampus from the 5xFAD Alzheimer’s Disease mouse model

Project description:Suspension TRAPping filter (sTRAP) is an attractive sample preparation method for proteomics study. Here, we demonstrated the use of a low-cost Plasmid DNA spin column for sTRAP. We first evaluated, the reproducibility of this protocol and the low CoV using 4 replicates of 5-10 µg of a synapse enriched fraction, with 120 ng of the resulting tryptic peptides for mass spectrometry resulted in 5500 protein groups identification with CoV of 3.5%. We have also tested lower input amounts of 0.6 µg and 0.3 µg with CoV increase slightly to 5-8%. Comparing other sample preparation protocols, as the in-gel digestion and the commercial protifi sTRAP with the plasmid DNA micro-spin, the last is superior in both protein and peptide identification numbers (48523, 56714 to 60245 peptides and 5669, 6106, 6494 proteins respectively) and smaller Coefficient of Variation ( 6.7%, 3.2%, 3.1% respectively).We applied this protocol to the analysis of hippocampal proteome from a mouse model of Alzheimer’s disease, and identified about 6300 protein groups with CV of 11.6-14.6%. Protein changes in the mutant mice points to the alteration of processes related to known major AD-related pathology.

2023-05-23 | PXD041045 | Pride

Characterization of the chromatin accessibility in an Alzheimer’s disease (AD) mouse model (RNA-Seq)

Project description:The assay for transposase-accessible chromatin by sequencing (ATAC-seq) was used to investigate the AD-associated chromatin reshaping in the APPswe/PS1dE9 (APP/PS1) mouse model. ATAC-seq data in the hippocampus of 8-month-old APP/PS1 mice were generated, and the relationship between chromatin accessibility and gene expression was analyzed in combination with RNA-sequencing.We identified 1690 increased AD-associated chromatin accessible regions in the hippocampal tissues of APP/PS1 mice and 1003 decreased chromatin accessible regions were considered to be related with declined AD-associated biological processes.In the APP/PS1 hippocampus, 1090 genes were found to be up-regulated and 1081 down-regulated. Interestingly, enhanced ATAC-seq signal was found in approximately 740 genes, with 43 exhibiting up-regulated mRNA levels.Our study reveals that alterations in chromatin accessibility may be an initial mechanism in AD pathogenesis.

2020-07-09 | GSE145907 | GEO

Characterization of the chromatin accessibility in an Alzheimer’s disease (AD) mouse model (ATAC-Seq)

2020-07-09 | GSE145906 | GEO

Alzheimer Disease (AD) and AD model detergent insoluble proteomes

Project description:Characterizing the detergent insoluble brain proteome of sporadic late-onset Alzheimer’s disease (LOAD) has identified proteins and pathways associated with disease pathogenesis. Similar studies in early onset Alzheimer’s disease cases due to presenilin-1 mutations (PS1-EOAD), along with more detailed correlations with insoluble proteomes from LOAD and AD transgenic rodents, are limited. We therefore utilized quantitative proteomics to identify proteins that were significantly changing in the PS1-EOAD insoluble proteome versus controls. Comparison with the LOAD insoluble proteome identified common pathologic AD markers in addition to unique PS1-EOAD insoluble proteins. Similarly, weighted correlation network analysis (WGCNA) identified PS1-EOAD and LOAD co-expression modules with both like and disparate expression levels. Finally, we compared the human PS1-EOAD insoluble proteome to transgenic AD mouse and rat insoluble proteomes to understand how well these models mimic the human disease. Although many common AD pathologic findings were found in the rodents, there were multiple PS1-EOAD proteome changes not well recapitulated in the animal models. These proteomic studies highlight unique PS1-EOAD proteome changes as compared to LOAD and identify limitations to using AD transgenic rodents to study some aspects of AD.

2019-06-25 | PXD005321 | Pride

Alzheimer Disease model detergent insoluble proteomes

2022-03-01 | PXD005347 | Pride

Multi-omics approach to characterize sex-specific metabolic alterations in triple-transgenic Alzheimer's mouse brain

Project description:We aimed to characterise alterations in metabolic pathways and proteome composition in a mouse model of Alzheimer disease (AD). We specifically aimed to evaluate how these differences may be sex-specific by integrative multi-omics analysis (metabolites, lipids, proteins).

2023-03-11 | PXD033164 | Pride

Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial

Project description:Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD). The mechanism of action (MOA) of crisaborole and its effects on lesional measures of disease severity are not yet well-defined. This phase 2a, single-center, vehicle-controlled, intrapatient study was designed to further characterize the MOA of crisaborole through evaluation of clinical efficacy and changes in skin biomarkers in adults (N = 40) with mild-to-moderate AD.

2019-06-29 | GSE133477 | GEO

Interactomes of GluA1 and GluA3 subunit containing AMPARs reveal distinct protein composition

Project description:The AMPA glutamate receptor (AMPAR) is the major type of synaptic excitatory ionotropic receptor in the brain. The most abundant AMPAR subtypes in the hippocampus are GluA1/2 and GluA2/3 heterotetramers. Each subtype contributes differentially to mechanisms of synaptic plasticity, which may be in part caused by how these receptors are regulated by specific associated proteins. A broad range of AMPAR interacting proteins have been identified and several were shown to affect biogenesis, AMPAR trafficking, and channel properties, alone or in distinct assemblies, and several revealed preferred binding to specific AMPAR subunits. To date, a systematic separate interactome analysis of the major GluA1/2 and GluA2/3 AMPAR subtypes is lacking. To reveal interactors belonging to specific AMPAR sub-complexes, we performed both quantitative and interaction proteomics on hippocampi of wildtype and GluA1- or GluA3 knock-out mice. Whereas GluA1/2 receptors co-purified TARP-γ8, PRRT1 and CNIH2 with highest abundances, GluA2/3 receptors revealed strongest co-purification of CNIH2, TARP-γ2, and OLFM1. Further analysis revealed that TARP-γ8-PRRT1 can interact directly, and co-assemble into an AMPAR subcomplex especially near the synapse.

2022-12-12 | PXD031603 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data